Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Brazil coronavirus outbreak worsens as country could soon be No. 2 in cases

Published 05/20/2020, 06:06 PM
Updated 05/20/2020, 07:36 PM
© Reuters. Outbreak of the coronavirus disease (COVID-19), in Sao Paulo

By Pedro Fonseca and Eduardo Simões

RIO DE JANEIRO/SAO PAULO (Reuters) - Brazil's coronavirus outbreak worsened on Wednesday and the South American nation could soon have the second-highest number of cases in the world as the Health Ministry reported 888 new deaths and nearly 20,000 new infections in a single day.

Brazil might soon trail only the United States in the number of coronavirus cases. Russia currently has the second-highest number of cases. Brazil's coronavirus death toll is 18,859.

Brazil's confirmed case tally now stands at 291,579, according to the Health Ministry. On Monday, Brazil overtook Britain to become the country with the third-highest number of infections and registered a daily record of 1,179 deaths on Tuesday.

President Jair Bolsonaro has been widely criticized for his handling of the outbreak. The far-right former army captain has long snubbed social-distancing measures, arguing instead for the reopening the economy.

He has also become an increasingly strong advocate for the malaria drug chloroquine as a possible remedy for COVID-19, despite warnings from health experts.

On Wednesday, the Health Ministry issued new guidelines for wider use of anti-malarial drugs in mild coronavirus cases.

Interim Health Minister Eduardo Pazuello, an active-duty army general, authorized the modified protocol after two trained doctors left the ministry's top job under pressure to promote the early use of chloroquine and hydroxychloroquine.

"We are at war. Worse than defeat would be the shame of not putting up a fight," Bolsonaro tweeted about the government decision to put forward the drugs without proof of their effectiveness.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Gonzalo Vecina Neto, the former head of Brazil's health regulator, Anvisa, called the new measures a "barbarity" that could cause more harm than good because of the dangerous potential side effects of the drug.

"It has no scientific evidence," Vecina Neto told Reuters. "(It is) unbelievable that in the 21st century, we are living off magical thinking."

Latest comments

It works, thay all I have to say. Those try so hard to keep it away from the patients have their own politically agendas.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.